Libya vs Malaysia: Cause of death, by non-communicable diseases, ages 0-4, male
Libya
41.5%
in 2021
Malaysia
41.8%
in 2021
Libya rank
36th
Malaysia rank
34th
Cause of death, by non-communicable diseases, ages 0-4, male over time
- Libya
- Malaysia
How they compare
Malaysia currently reports 41.8% against 41.5% in Libya, a difference of 0.3%.
Across all 6 years both countries report, Malaysia has been ahead every year.
Libya ranks 36th and Malaysia ranks 34th of 185 countries.
Malaysia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Libya | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 28.3% | 40.7% | 12.4% | Malaysia |
| 2010s | 38.9% | 42.3% | 3.4% | Malaysia |
| 2020s | 41.3% | 42.2% | 0.9% | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, ages 0-4, male, Libya or Malaysia?
- Malaysia, at 41.8% against 41.5% in Libya as of 2021.
- What is the difference in cause of death, by non-communicable diseases, ages 0-4, male between Libya and Malaysia?
- 0.3%, with Malaysia ahead.
- How many years of comparable data are there for Libya and Malaysia?
- 6 years are reported by both, from 2000 to 2021.
- How do Libya and Malaysia rank globally for cause of death, by non-communicable diseases, ages 0-4, male?
- Libya ranks 36th and Malaysia ranks 34th of 185 countries.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, ages 0-4, male (% of total male deaths ages 0-4). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of male deaths ages 0-4 due to non-communicable diseases divided by number of all male deaths ages 0-4, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.